62 results on '"Escudero, Pilar"'
Search Results
2. Improving pulse oximetry accuracy in dark-skinned patients: technical aspects and current regulations
3. Características sociales de la población con infección COVID-19 de un centro de salud en cuatro olas consecutivas de la pandemia
4. Are Activity Wrist-Worn Devices Accurate for Determining Heart Rate during Intense Exercise?
5. Skin Pigmentation Influence on Pulse Oximetry Accuracy: A Systematic Review and Bibliometric Analysis
6. Oxygen Saturation Behavior by Pulse Oximetry in Female Athletes: Breaking Myths
7. Bioanalytical Detection of Steroid Abuse in Sports Based on the Androgenic Activity Measurement
8. Martial arts injuries: a longitudinal study about judo, karate and wushu carried out in the Community of Madrid, Spain
9. Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
10. Position statement of the Royal Spanish Football Federation for the resumption of football activities after the COVID-19 pandemic (June 2020)
11. First-line biological agents plus chemotherapy in elderly patients with metastatic colorectal cancer: A retrospective pooled analysis.
12. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
13. Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti–Epidermal Growth Factor Receptor Therapy
14. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
15. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
16. Impact of the UGT2B17 polymorphism on the steroid profile. Results of a crossover clinical trial in athletes submitted to testosterone administration
17. Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
18. First-line treatment with panitumumab plus FOLFIRI in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.
19. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
20. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
21. Expression and correlation of HLA-G and sHLA-G as prognostic factors in renal cell carcinoma.
22. Impact of UGT2B17 gene deletion on the steroid profile of an athlete
23. Gene expression markers of resistance to capecitabine-oxaliplatin-bevacizumab treatment in metastatic colorectal cancer (mCRC).
24. Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Español Multidisciplinar en Cancer Digestivo (GEMCAD)
25. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features
26. Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer
27. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy
28. Correlation of VEGFR2 expression in tumor tissue with longer progression-free survival in patients with neuroendocrine tumors (NETs) treated with pazopanib.
29. Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.
30. Pazopanib activity in pancreatic neuroendocrine tumors (pNETs).
31. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review
32. Chemoradiation (CRT) followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant CRT and surgery for locally advanced rectal cancer: Results of the Spanish GCR-3 randomized phase II trial after a median follow-up of 5 years.
33. sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.
34. Correlation of hypertension and proteinuria with outcomes in elderly bevacizumab (BEV)-treated patients with metastatic colorectal cancer (mCRC): Analysis of the BECOX and BECA studies.
35. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer
36. Gene‐expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5′fluoruracil‐based adjuvant chemotherapy
37. Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II–III rectal cancer
38. Influence of BRAF mutations and RAC1b/RAC1 mRNA expression ratio on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy.
39. Garantías internacionales y derechos electorales : una aproximación bibliográfica
40. Transanal endoscopic microsurgery for rectal cancer. Long-term oncologic results
41. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: A GEMCAD study
42. La pulsioximetría y su aplicación en pruebas de esfuerzo máximo
43. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab
44. Bibliografía sobre el sistema electoral alemán
45. Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study
46. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
47. Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer
48. Phase II Trial of Preoperative Irinotecan–Cisplatin Followed by Concurrent Irinotecan–Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma
49. Materiales para el estudio de la técnica legislativa
50. Local Full-Thickness Excision as First Line Treatment for Sessile Rectal Adenomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.